@article{CCO28769,
author = {Shawn Kothari and Everett E. Vokes},
title = {Immune subgroups and the tumor microenvironment as a potential new biomarker to assess response to immunotherapy},
journal = {Chinese Clinical Oncology},
volume = {8},
number = {Suppl 1},
year = {2019},
keywords = {},
abstract = {Immunotherapy has emerged as a new standard of care therapeutic option for patients with recurrent or metastatic Head and Neck Squamous Cell Carcinoma. Following the recent presentation of Keynote-048, the use of Pembrolizumab either as a single agent or in combination with chemotherapy can be considered as first-line treatment for patients with measurable PD-L1 in their tumor or microenvironment (1).},
issn = {2304-3873}, url = {https://cco.amegroups.org/article/view/28769}
}